Diltiazem enhances the effects of triazolam by inhibiting its metabolism

Clinical Pharmacology and Therapeutics
A VarheP J Neuvonen

Abstract

Triazolam is metabolized by CYP3A4. Diltiazem is an inhibitor of this isozyme and interacts with midazolam, another substrate of this enzyme. Therefore the possible interaction between triazolam and diltiazem is worth investigation. A balanced, randomized, double-blind crossover study design was used, with an interval of 2 weeks between phases. Ten healthy volunteers were given 60 mg diltiazem orally or placebo three times a day for 2 days. On the second day they received a single 0.25 mg oral dose of triazolam, after which plasma samples were collected and effects of triazolam measured for up to 17 hours. Diltiazem increased the mean area under the triazolam concentration-time curve threefold (p < 0.001) and the elimination half-life (p < 0.001) and the peak plasma concentration of triazolam twofold (p < 0.005). The increased concentrations of triazolam during the diltiazem phase were associated with increased and prolonged pharmacodynamic effects. Diltiazem has a clinically significant interaction with oral triazolam. The data is highly suggestive that diltiazem inhibits the metabolism of triazolam during the first-pass and elimination phases. Prescription of triazolam should be avoided if a patient is using diltiazem or othe...Continue Reading

References

Jul 22, 1992·Biochemical Pharmacology·C M HuntG M Stave
Nov 1, 1991·Clinical Pharmacokinetics·K D SchlanzM B Bottorff
Dec 1, 1991·Clinical Pharmacokinetics·K D SchlanzM B Bottorff
May 1, 1988·Clinical Pharmacology and Therapeutics·E SteinerR Dahlqvist
May 1, 1986·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·J GenestP Kwiterovich
Aug 1, 1986·Clinical Pharmacology and Therapeutics·G CarrumD R Abernethy
Aug 1, 1986·Clinical Pharmacology and Therapeutics·L A BauerL Greene
Aug 1, 1995·Clinical Pharmacology and Therapeutics·S K HukkinenP J Neuvonen
Mar 1, 1994·British Journal of Clinical Pharmacology·J T BackmanP J Neuvonen
Dec 1, 1993·Clinical Pharmacology and Therapeutics·D W RobinA J Wood
Feb 1, 1993·Pharmacology & Therapeutics·A K DalyJ R Idle

❮ Previous
Next ❯

Citations

Sep 6, 2000·British Journal of Clinical Pharmacology·A L MasicaD R Jones
Feb 11, 2011·British Journal of Anaesthesia·P J PereP H Rosenberg
May 23, 1998·Annual Review of Pharmacology and Toxicology·K E Thummel, G R Wilkinson
May 9, 2002·Drug Metabolism Reviews·Slobodan Rendic
Oct 21, 2017·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Larry HouseMark J Ratain
Jan 1, 1997·Clinical Pharmacology and Therapeutics·K VillikkaP J Neuvonen
Dec 9, 1997·Clinical Pharmacology and Therapeutics·K M KaukonenP J Neuvonen
Jul 15, 1998·Clinical Pharmacology and Therapeutics·T S LambergP J Neuvonen
Sep 5, 1998·Clinical Pharmacology and Therapeutics·T KantolaP J Neuvonen
Nov 3, 1998·Clinical Pharmacology and Therapeutics·N E AzieS D Hall
Jan 19, 2008·Periodontology 2000·Elliot V Hersh, Paul A Moore
Aug 5, 2000·Clinical Pharmacokinetics·E L Michalets, C R Williams
Dec 31, 2008·American Journal of Therapeutics·Judy W M ChengWilbert S Aronow
May 8, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Xin ZhangStephen D Hall
May 1, 1997·The Annals of Pharmacotherapy·B L Lobo, W L Greene
Feb 13, 2010·Journal of Clinical Pharmacology·Joyce H S YouBrian Tomlinson
Oct 14, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Aleksandra GaletinJ Brian Houston
Nov 26, 2011·Expert Review of Clinical Pharmacology·Karen Rowland YeoAmin Rostami-Hodjegan
Nov 30, 2018·Current Drug Metabolism·Panjasaram Naidoo, Manoranjenni Chetty
Mar 2, 2010·Disease-a-month : DM·Judy W M ChengWilbert S Aronow
May 5, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·K Rowland YeoG T Tucker

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Acta Psychiatrica Scandinavica. Supplementum
R E HaddockF R Woods
British Journal of Clinical Pharmacology
T E Jones, R G Morris
Clinical Pharmacology and Therapeutics
N E AzieStephen D Hall
© 2021 Meta ULC. All rights reserved